BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:For decades\, RAS proteins have been considered “undruggable.”
  This all changed following the recent approval of the first-ever targete
 d KRAS G12C therapy\, marking a major landmark for this community. This b
 reakthrough has certainly laid out a roadmap for future success\, with mo
 re investment and innovation in the field than ever before\, particularly
  within emerging discovery strategies being pursued by the biopharma indu
 stry.\n\nAlong with this success\, significant efforts are now being plac
 ed within discovery of drugs that treat a broader range of RAS mutants be
 yond G12C. The 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit\, will
  shine a spotlight onto pioneering discovery effort targeting the RAS/MAP
 K pathway\, and benchmark the various innovative modalities being harness
 ed to target RAS mutations beyond G12C\, giving you the opportunity to es
 tablish and accelerate your drug discovery platform by targeting the RAS/
 MAPK pathway at every turn.\n
DTEND:20220224T153000
DTSTAMP:20260421T101850Z
DTSTART:20220222T090000
LOCATION:Online\, 1 Avenue de Lafayette\, Boston\, Massachusetts\, 02111\,
SEQUENCE:0
SUMMARY:For decades\, RAS proteins have been considered “undruggable.” Thi
 s all changed following the recent approval of the first-ever targeted KR
 AS G12C t...
UID:b37b72ba-9139-4e75-9b4a-2b098e6c320d
END:VEVENT
END:VCALENDAR